Skip to content

Establishment of a Tumor Bank for Blood Samples

Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01763125
Enrollment
10000
Registered
2013-01-08
Start date
2003-11-30
Completion date
2026-12-31
Last updated
2023-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms, Colorectal Neoplasms, Endocrine Gland Neoplasms, Lung Neoplasms, Neoplasms of the Female Genitalia, Ovarian Neoplasms

Keywords

circulating tumor cells, CTC, tumor marker

Brief summary

Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

Detailed description

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of translational oncology will only increase in the future -From bench to bedside - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient. Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research. The aim of this tumor bank is to consist of biological samples (together with a tissue bank - see EK 260/2003) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

Interventions

OTHERBlood collection

Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male/Female * Age 18 to 90 years max. * Just one current known malignant disease or * Just one current inflammatory disease

Exclusion criteria

* Inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage

Design outcomes

Primary

MeasureTime frame
Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.14 years

Countries

Austria, Belgium, Germany, Italy

Contacts

Primary ContactRobert Zeillinger, Prof. Dr.
robert.zeillinger@meduniwien.ac.at+43140400
Backup ContactEva Obermayr, PhD
eva.obermayr@muv.ac.at+43140400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026